Literature DB >> 10787412

Aspartate 351 of estrogen receptor alpha is not crucial for the antagonist activity of antiestrogens.

S I Anghel1, V Perly, G Melançon, A Barsalou, S Chagnon, A Rosenauer, W H Miller, S Mader.   

Abstract

The antagonist activity of antiestrogens is due to the presence of a long carbon side chain at positions 7alpha or 11beta or equivalent on their steroid or steroid-like skeletons. These side chains establish hydrophobic interactions with amino acids of the estrogen receptor alpha (ERalpha) ligand binding domain. In addition, a hydrogen bond formed between amino acid Asp-351 and the tertiary amine present at the end of the side chain of partial antiestrogens is considered to be crucial for their antiestrogenicity. Here, we have investigated the role of Asp-351 in antiestrogen action in transiently transfected HeLa and MDA-MB-231 cells. Our results indicate that disruption of the negative charge at position 351 does not increase the agonist activity of partial antiestrogens and thus that the hydrogen bond with the antiestrogen side chain is not determinant in positioning the side chain in an antagonist position. The negative charge at position 351 was not required for transcriptional activity in the presence of hormone, but its presence was necessary for basal activity of the wild-type receptor and constitutive activities of mutants L536P and Y537A, suggesting a role of Asp-351 in stabilizing the active conformation of ERalpha. This stabilizing role of Asp-351 could be due to interaction of Asp-351 with the amide group of the peptide bond between Leu-539 and Leu-540 in helix 12 observed in the active conformation of the ERalpha ligand binding domain.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10787412     DOI: 10.1074/jbc.M002098200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  5 in total

1.  Structure-function relationships of the raloxifene-estrogen receptor-alpha complex for regulating transforming growth factor-alpha expression in breast cancer cells.

Authors:  Hong Liu; Woo-Chan Park; David J Bentrem; Kevin P McKian; Alexander De Los Reyes; Jessica A Loweth; Jennifer MacGregor Schafer; James W Zapf; V Craig Jordan
Journal:  J Biol Chem       Date:  2001-12-20       Impact factor: 5.157

2.  Transactivation Function-2 of Estrogen Receptor α Contains Transactivation Function-1-regulating Element.

Authors:  Yukitomo Arao; Laurel A Coons; William J Zuercher; Kenneth S Korach
Journal:  J Biol Chem       Date:  2015-05-31       Impact factor: 5.157

3.  Genomic modelling of the ESR1 Y537S mutation for evaluating function and new therapeutic approaches for metastatic breast cancer.

Authors:  A Harrod; J Fulton; V T M Nguyen; M Periyasamy; L Ramos-Garcia; C-F Lai; G Metodieva; A de Giorgio; R L Williams; D B Santos; P J Gomez; M-L Lin; M V Metodiev; J Stebbing; L Castellano; L Magnani; R C Coombes; L Buluwela; S Ali
Journal:  Oncogene       Date:  2016-10-17       Impact factor: 9.867

4.  Structure-based analysis of the ultraspiracle protein and docking studies of putative ligands.

Authors:  Souphatta Sasorith; Isabelle M L Billas; Thomas Iwema; Dino Moras; Jean-Marie Wurtz
Journal:  J Insect Sci       Date:  2002-12-03       Impact factor: 1.857

5.  Ribociclib Induces Broad Chemotherapy Resistance and EGFR Dependency in ESR1 Wildtype and Mutant Breast Cancer.

Authors:  Isabel Mayayo-Peralta; Beatrice Faggion; Liesbeth Hoekman; Ben Morris; Cor Lieftink; Isabella Goldsbrough; Lakjaya Buluwela; Joseph C Siefert; Harm Post; Maarten Altelaar; Roderick Beijersbergen; Simak Ali; Wilbert Zwart; Stefan Prekovic
Journal:  Cancers (Basel)       Date:  2021-12-16       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.